Richmond Pharmacology is delighted with the acknowledgement and features at 96 in the list of 200.

The report is the first of its kind and refers to the high-growth companies founded or led by women or have management teams that are at least 50% women.

Richmond Pharmacology qualifies for the list as it was co-founded by Medical Director Dr Ulrike Lorch and has equal representation in senior management roles throughout the business.

J.P. Morgan Private Bank's list of the top 200 female-powered businesses showcases private UK businesses that have grown sales, headcount or valuation at exceptional rates. To be eligible, companies must have grown at least one of these metrics and observed this growth in the 12 months prior to 31 October 2020. In total, it analyses the 6,085 high growth companies in the UK which meet the criteria.

Dr Ulrike Lorch commenting on the success, said, "We are delighted that Richmond Pharmacology has been recognised as one of the top high-growth companies where women form a significant proportion of the founder and leadership teams. It has been a rewarding journey from founding the company to where we are now: an innovative and highly specialised team of people who play an essential part in the development of new medicines. Men and women have always had equal roles at Richmond Pharmacology - from entry positions to the boardroom - and we share our success as a collective."

Richmond Pharmacology is proud of our diverse and inclusive culture. Currently, women contribute to over half of the collective workforce. Learn more about the JP Morgan Top 200 Female Powered Businesses. Download the report here.

Latest news

Futureproofing early phase clinical research for the next generation of investigators.

March 20, 2023
Richmond Pharmacology’s experienced Principal investigators and Co-investigators recently gave expert feedback on the ICH M11 (CeSHarP) protocol template.
Read more

Director of Operations, Keith Berelowitz, has been appointed as the Research Ethics Committee Chair for the Health Research Authority.

January 19, 2023
Keith Berelowitz will be responsible for ensuring that all ethical possibilities are explored in relation to new research.
Read more

Events

13th International Workshop on Regulatory Requirements and Current Scientific Aspects on the Preclinical and Clinical Investigation of Drug-Drug Interactions

Sunday, June 4th to Tuesday June 6th 2023
Exchange research-based knowledge on drug-drug interactions (DDIs) among all interested stakeholders from pharmaceutical industry, regulatory authorities, academic and health care delivery backgrounds and perspectives.
View event